Julia Karow tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb. Follow her on Twitter at @Julia_Karow.
New York City Department of Health and Mental Hygiene researchers discovered almost 700 bacterial species in the city's drinking water, including samples before and after treatment.
Initiated the by New York Genome Center Cancer Group, the Polyethnic-1000 project will focus on cancer patients from ethnic minority groups.
The app provides results for 15 genetic conditions in the areas of carrier screening, genetic disease risk, medication response, and health-related traits.
The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.
The VGP released its first 15 high-quality reference genome assemblies today, which are part of the project's first phase to sequence 260 vertebrate genomes.
Starting in early 2019, Yale plans to sign up at least 100,000 patients to analyze their genomes and EHR data for research and return of clinically actionable results.
The Menlo Park, California-based company plans to demonstrate its sequencing technology on a small genome in the near future.
To nudge genetic testing labs to share their variant data, MGH now requires that labs to which it sends tests to contribute variants to the ClinVar database.
The firm is preparing to launch its first kits and has identified cancer detection and monitoring as well as genotoxicity testing as initial applications.
The syndromes — HLRCC and SDH PGL/PCC — suppress DNA repair by homologous recombination, rendering tumors vulnerable to PARP inhibitors.
Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.
The New York Times reports on the shifting interpretations of what some genetic variants mean over time.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.